JUL 2 2 2003

510(k) Summary

This 510(k) Summary for the EBI® SpineLink® - II Spinal Fixation System is provided as required per Section 513(3) of the Food, Drug and Cosmetic Act.

1. Submitter: EBI, L.P. Contact Person: Frederic Testa, RAC

100 Interpace Parkway Telephone: (973) 299-9300, ext.2208

Parsippany, NJ 07054

Date prepared: June 30, 2003

2. Proprietary Name: EBI® SpineLink® - II Spinal Fixation System

Common Name: Spinal Fixation Device

Classification Names: Spinal Intervertebral Body Fixation Orthosis

3. Predicate or legally marketed devices that are substantially equivalent:

- Spinal Concepts BacFix Spinal Fixation System (K013887)
- Sofamor Danek CD Spinal System (K964159)
- Sofamor Danek Townley Pedicle Screw Plating System (K983706)
- **4. Description of the device:** The EBI[®] SpineLink[®] II Spinal Fixation System is a spinal fixation device that utilizes interconnecting links, screws (fixed and polydirectional designs), transverse connectors, hooks, endcaps, locknuts, and link ties.
- **5. Intended Use:** The EBI[®] SpineLink[®] II Spinal Fixation System is a non-cervical spinal fixation device intended for use as a pedicle screw fixation system, a posterior hook and sacral/iliac screw fixation system, or as an anterolateral fixation system.

Pedicle screw fixation is limited to skeletally mature patients. The device is indicated for all of the following indications regardless of the intended use: degenerative disc disease (defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies), spondylolisthesis, trauma (i.e., fracture or dislocation), deformities or curvatures (i.e., scoliosis, kyphosis, and or lordosis), tumor, stenosis, pseudoarthrosis, and failed previous fusion. The transverse connector is not intended for anterior/anterolateral fixation.

- 6. Materials: The components of the System are manufactured from titanium alloy (Ti-6A1-4V ELI) per ASTM F136.
- 7. Comparison of the technological characteristics of the device to predicate devices: There are no significant differences between the EBI® SpineLink® II Spinal Fixation System and other legally marketed spinal systems. It is substantially equivalent* to the predicate devices in regards to intended use, materials, and function. Mechanical testing comparing the System to predicate systems demonstrates that the device complies with applicable standards and meets all of its functional requirements.

^{*}Any statement made in conjunction with this submission regarding a determination of substantial equivalence to any other product is intended only to relate to whether the product can be lawfully marketed without pre-market approval or reclassification and is not intended to be interpreted as an admission or any other type of evidence in patent infringement litigation. [Establishment Registration and Premarket Notification Procedures, Final Regulation, Preamble, August 23, 1977, FR 42520 (Docket No. 76N-0355.)]



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JUL 2 2 2003

Mr. Jon Caparotta, RAC Manager, Regulatory Affairs EBI, L.P. 100 Interpace Parkway Parsippany, New Jersey 07054

Re: K031355

Trade Name: EBI[®] SpineLink[™] II Spinal Fixation System Regulation Number: 21 CFR 888.3070, 888.3060, 888.3050

Regulation Name: Pedicle screw spinal system, Spinal intervertebral body fixation

orthosis, Spinal interlaminal fixation orthosis

Regulatory Class: III

Product Code: NKB, MNI, MNH, KWQ, KWP

Dated: April 28, 2003 Received: April 30, 2003

Dear Mr. Caparotta:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Statement of Indications for Use

		Page 1 of 1
510(k) Number (if known):	K031355	
Device Name: EBI® SpineLink®	- II Spinal Fixati	on System
Indications For Use:		
The EBI® SpineLink® II Spinal Fixa	tion System is a nor	n-cervical spinal fixation device intended for use a
a pedicle screw fixation system, a po	sterior hook and sa	cral/iliac screw fixation system, or as an
anterolateral fixation system. Pedicl	e screw fixation is l	limited to skeletally mature patients. The device is
indicated for all of the following ind	ications regardless	of the intended use: degenerative disc disease
(defined as discogenic back pain wit	h degeneration of th	ne disc confirmed by history and radiographic
studies), spondylolisthesis, trauma (i	.e., fracture or dislo	ocation), deformities or curvatures (i.e., scoliosis,
kyphosis, and or lordosis), tumor, ste	enosis, pseudoarthro	osis, and failed previous fusion. The transverse
connector is not intended for anterior	r/anterolateral fixati	ion.
(PLEASE DO NOT WRITE B IF NEEDED)	ELOW THIS L	INE-CONTINUE ON ANOTHER PAGE
Concurrenc	e of CDRH, Off	ice of Device Evaluation (ODE)
Prescription Use	OR	Over-The-Counter Use
(Per 21 CFR 801.109)		(Optional Format 1-2-96)